PARNUTS revision
Industry backs vote to amend PARNUTs framework
European industry and consumer groups have broadly backed draft amendments to the much-debated specialised foods Directive known as PARNUTs.
Archives for March 1, 2012
Monthly career insider
Dairy NPD veteran: “Grass won’t grow faster when you start pulling the blades.”
In this month’s Career Insider, we get a taste of beverage development at a leading dairy ingredients company. It’s more than just a creative “fuzzy front end”…
EU approval opens new doors for resveratrol
Fluxome has won novel foods approval to use its fermented resveratrol form in food supplements in the European Union’s 27 member states.
GSK pitches new 'functional' Ribena at young women in large-scale launch
GlaxoSmithKline (GSK) is set to launch a new ‘functional’ Ribena range in the UK this week – its largest drinks launch in 20 years – with new packaging designed to appeal to its “two key target audiences” in young women and mothers.
TSI forms two global divisions to double sales within three years
TSI Group is splitting into two strategic divisions – Value Services and Innovation Products – as the Hong Kong registered company aims to double existing corporate business by 2015.
High-dose vitamin D may alleviate menstrual cramps: Study
Women who experience painful menstrual cramps could find relief from high-dose vitamin D3, according to new research – which suggests the dietary supplement could provide an alternative to painkilling drugs that are currently used.
Multivitamins may boost short-term memory, says meta-analysis
A daily multivitamin may improve immediate recall memory, according to a meta-analysis of 10 randomized, placebo-controlled trials.
Abbott to build $270m nutrition manufacturing facility in Ohio
Abbott Nutrition has unveiled plans to build a $270m nutrition manufacturing facility in Tipp City, Ohio, to make liquid nutrition products Ensure and Glucerna for the North American market.
OmniActive gets FDA GRAS for Lutemax 2020 ingredient
The U.S. Food and Drug Administration (FDA) has issue a letter of no objection to the GRAS (Generally Recognized As Safe) status of OmniActive’s eye health ingredient Lutemax 2020.